{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:04:20Z","timestamp":1791515060818,"version":"4.3.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["Venture Grant"],"award-info":[{"award-number":["Venture Grant"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["TP834128"],"award-info":[{"award-number":["TP834128"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000991","name":"Faculty of Medicine, Nursing and Health Sciences, Monash University","doi-asserted-by":"publisher","award":["FLPF23-1952570271"],"award-info":[{"award-number":["FLPF23-1952570271"]}],"id":[{"id":"10.13039\/501100000991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000991","name":"Faculty of Medicine, Nursing and Health Sciences, Monash University","doi-asserted-by":"publisher","award":["Bridging Fellowship"],"award-info":[{"award-number":["Bridging Fellowship"]}],"id":[{"id":"10.13039\/501100000991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2026555"],"award-info":[{"award-number":["2026555"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2011391"],"award-info":[{"award-number":["2011391"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2011391"],"award-info":[{"award-number":["2011391"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","award":["PIRAYI-0322"],"award-info":[{"award-number":["PIRAYI-0322"]}],"id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001114","name":"Endocrine Society of Australia","doi-asserted-by":"publisher","award":["Postdoctoral Award"],"award-info":[{"award-number":["Postdoctoral Award"]}],"id":[{"id":"10.13039\/501100001114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","award":["RSP-515-2024"],"award-info":[{"award-number":["RSP-515-2024"]}],"id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["MCRF15023"],"award-info":[{"award-number":["MCRF15023"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA radioligand therapy targets metastatic castration-resistant prostate cancer by delivering radiation to cells expressing prostate-specific membrane antigen (PSMA). While some patients show remarkable responses, up to 50% show little to no benefit, and disease progression inevitably occurs. Eligibility is mainly based on PSMA avidity by PET imaging, yet responses remain highly variable, highlighting a disconnect between PSMA expression and clinical efficacy. This study used PSMA-positive patient-derived xenografts (PDXs) from the Melbourne Urological Research Alliance (MURAL) to explore mechanisms of response and resistance to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PDXs with variable PSMA expression were treated with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T and assessed for radioligand uptake and DNA damage. Histological, genomic and transcriptomic analyses aimed to identify features of radiosensitivity and resistance at a tissue and cellular level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PDXs recapitulated clinical PSMA histology and exhibit variable responses to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA, mirroring the heterogeneity observed in the clinic. Responses ranged from sustained, transient or delayed tumor reduction to treatment resistant, including a remarkable responder with complete tumor regression for up to 20 weeks post treatment. The magnitude and persistence of DNA damage and tumor cell death varied between PDXs, demonstrating divergent radiosensitivity due to intrinsic tumor characteristics. These characteristics included PSMA receptor density, extent of DNA damage, genomic aberrations and baseline transcriptomic signatures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings in PDX tumors emphasize the complexity of predicting [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA response, beyond what cell line models can capture. Comparable radiation doses with variable regression underscores that radiosensitivity is multifactorial across diverse tumors, supporting the need for integrated multimodal approaches for patient stratification. Integrating baseline genomic and transcriptomic profiles may reveal determinants of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA sensitivity to improve patient selection and identify novel combination therapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03659-w","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:04:14Z","timestamp":1770951854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&amp;T in patient-derived models of prostate cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Isabel M.","family":"Everard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"de Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Keerthikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Sivaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B.","family":"Haskali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail P.","family":"Risbridger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2650-3365","authenticated-orcid":false,"given":"Laura H.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-2380","authenticated-orcid":false,"given":"Renea A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"3659_CR1","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-20-0209","volume":"26","author":"AS Ravi Kumar","year":"2020","unstructured":"Ravi Kumar AS, Hofman MS. Mechanistic insights for optimizing PSMA radioligand therapy. Clin Cancer Res. 2020;26:2774\u20136.","journal-title":"Clin Cancer Res"},{"key":"3659_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378.","journal-title":"Eur Urol"},{"key":"3659_CR3","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041.","journal-title":"Nat Commun"},{"key":"3659_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5603\/NMR.2023.0008","volume":"26","author":"T Sengoz","year":"2023","unstructured":"Sengoz T, Sen Turk N, Ozlulerden Y, Celen S, Gultekin A, Yaylali O, Yuksel D. Confirmation of PSMA expression measured on [68Ga]Ga-PSMA PET\/CT by immunohistochemistry in prostate adenocarcinoma. Nucl Med Rev Cent East Eur. 2023;26:68\u201373.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"3659_CR5","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, et al. Investigating PSMA-Targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res. 2020;26:2946\u201355.","journal-title":"Clin Cancer Res"},{"key":"3659_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzbuhler","year":"2018","unstructured":"Kranzbuhler B, Salemi S, Umbricht CA, Muller C, Burger IA, Sulser T, Eberli D. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate. 2018;78:758\u201365.","journal-title":"Prostate"},{"key":"3659_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2967\/jnumed.119.232934","volume":"61","author":"E O\u2019Neill","year":"2020","unstructured":"O\u2019Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, et al. Imaging DNA damage repair in vivo after (177)Lu-DOTATATE therapy. J Nucl Med. 2020;61:743\u201350.","journal-title":"J Nucl Med"},{"key":"3659_CR8","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, Kessel K, Schafers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812\u201320.","journal-title":"Theranostics"},{"key":"3659_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pros.24549","volume":"83","author":"T Derlin","year":"2023","unstructured":"Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83:1076\u201388.","journal-title":"Prostate"},{"key":"3659_CR10","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic Castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION Trial). Radiology. 2024;312:e233460.","journal-title":"Radiology"},{"key":"3659_CR11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus Cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"3659_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and Meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane Antigen-targeted radioligand therapy in metastatic Castration-Resistant prostate cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"3659_CR13","doi-asserted-by":"crossref","unstructured":"Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA. A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and cctinium-225 in metastatic prostate cancer. Eur Urol. 2025;87:398\u2013408.","DOI":"10.1016\/j.eururo.2024.09.020"},{"key":"3659_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic Castrate-Resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312\u20139.","journal-title":"J Nucl Med"},{"key":"3659_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","volume":"87","author":"YH Dai","year":"2025","unstructured":"Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA. A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and quality of life outcomes following prostate-Specific membrane antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer. Eur Urol. 2025;87:398\u2013408.","journal-title":"Eur Urol"},{"key":"3659_CR16","doi-asserted-by":"publisher","first-page":"103108","DOI":"10.18632\/oncotarget.21600","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108\u201316.","journal-title":"Oncotarget"},{"key":"3659_CR17","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.7150\/thno.35759","volume":"9","author":"K Kessel","year":"2019","unstructured":"Kessel K, Seifert R, Schafers M, Weckesser M, Schlack K, Boegemann M, Rahbar K. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics. 2019;9:4841\u20138.","journal-title":"Theranostics"},{"key":"3659_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","volume":"25","author":"BM Prive","year":"2022","unstructured":"Prive BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, et al. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:71\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3659_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/pros.24450","volume":"83","author":"S Satapathy","year":"2023","unstructured":"Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience. Prostate. 2023;83:169\u201378.","journal-title":"Prostate"},{"key":"3659_CR20","doi-asserted-by":"publisher","first-page":"e17064","DOI":"10.1200\/JCO.2024.42.16_suppl.e17064","volume":"42","author":"S Dwabe","year":"2024","unstructured":"Dwabe S, Yazdanpanah O, Warnecke B, Benjamin DJ, Rezazadeh A, Mar N. Real-world treatment patterns with lutetium-177-PSMA-617 (<\u2009sup>177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:e17064\u2013e.","journal-title":"J Clin Oncol"},{"key":"3659_CR21","doi-asserted-by":"crossref","unstructured":"Maharaj M, Perrone E, Wirtz RM, Heslop L, Govender T, Korowlay NA, et al. Is extraordinary response and Long-Term remission of metastatic Castration-Resistant prostate cancer (mCRPC) after [177Lu]Lu-PSMA radioligand therapy due to an immunomodulatory effect (radiovaccination)? A dual center experience on superresponders. Cancers (Basel). 2025;17:476\u201390.","DOI":"10.3390\/cancers17030476"},{"key":"3659_CR22","first-page":"S12","volume":"62","author":"G Sgouros","year":"2021","unstructured":"Sgouros G, Dewaraja YK, Escorcia F, Graves SA, Hope TA, Iravani A, et al. Tumor response to radiopharmaceutical therapies: the knowns and the unknowns. J Nucl Med. 2021;62:S12\u201322.","journal-title":"J Nucl Med"},{"key":"3659_CR23","first-page":"1","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and Real-World use of Prostate-Specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book. 2022;42:1\u201317.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3659_CR24","doi-asserted-by":"publisher","first-page":"175883592311793","DOI":"10.1177\/17588359231179309","volume":"15","author":"L Kostos","year":"2023","unstructured":"Kostos L, Buteau JP, Hofman MS, Azad AA. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231179309.","journal-title":"Ther Adv Med Oncol"},{"key":"3659_CR25","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","volume":"12","author":"GP Risbridger","year":"2021","unstructured":"Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun. 2021;12:5049.","journal-title":"Nat Commun"},{"key":"3659_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/pros.23839","volume":"79","author":"LH Porter","year":"2019","unstructured":"Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, et al. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. Prostate. 2019;79:1326\u201337.","journal-title":"Prostate"},{"key":"3659_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/path.5652","volume":"254","author":"LH Porter","year":"2021","unstructured":"Porter LH, Bakshi A, Pook D, Clark A, Clouston D, Kourambas J, et al. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. J Pathol. 2021;254:121\u201334.","journal-title":"J Pathol"},{"key":"3659_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/nbt.3674","volume":"34","author":"K Alsop","year":"2016","unstructured":"Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat Biotechnol. 2016;34:1010\u20134.","journal-title":"Nat Biotechnol"},{"key":"3659_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","volume":"74","author":"MG Lawrence","year":"2018","unstructured":"Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, et al. Patient-derived models of Abiraterone- and Enzalutamide-resistant prostate cancer reveal sensitivity to Ribosome-directed therapy. Eur Urol. 2018;74:562\u201372.","journal-title":"Eur Urol"},{"key":"3659_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1172\/JCI40724","volume":"120","author":"SY Park","year":"2010","unstructured":"Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120:636\u201344.","journal-title":"J Clin Invest"},{"key":"3659_CR31","doi-asserted-by":"publisher","first-page":"97114","DOI":"10.18632\/oncotarget.21371","volume":"8","author":"YR Chung","year":"2017","unstructured":"Chung YR, Kim HJ, Kim YA, Chang MS, Hwang KT, Park SY. Diversity index as a novel prognostic factor in breast cancer. Oncotarget. 2017;8:97114\u201326.","journal-title":"Oncotarget"},{"key":"3659_CR32","doi-asserted-by":"crossref","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8:e162907.","DOI":"10.1172\/jci.insight.162907"},{"key":"3659_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy Pharmacology. 1989;24:148\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3659_CR34","doi-asserted-by":"crossref","unstructured":"Goffart S, Tikkanen P, Michell C, Wilson T, Pohjoismaki J. The type and source of reactive oxygen species influences the outcome of oxidative stress in cultured cells. Cells. 2021;10:1075.","DOI":"10.3390\/cells10051075"},{"key":"3659_CR35","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman A, Choo XY, Chew G, Ouyang JF, Sun G, Croft NP, et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat Commun. 2021;12:3015.","journal-title":"Nat Commun"},{"key":"3659_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3659_CR37","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"3659_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"3659_CR39","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u2013 5550.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3659_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1535-7163.MCT-23-0471","volume":"23","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, et al. Assessment of Patient-Derived xenograft growth and antitumor activity: the NCI PDXNet consensus recommendations. Mol Cancer Ther. 2024;23:924\u201338.","journal-title":"Mol Cancer Ther"},{"key":"3659_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11604-021-01230-5","volume":"40","author":"N Ota","year":"2022","unstructured":"Ota N, Yoshimoto Y, Darwis NDM, Sato H, Ando K, Oike T, Ohno T. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol. 2022;40:534\u201341.","journal-title":"Jpn J Radiol"},{"key":"3659_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijrobp.2022.02.014","volume":"113","author":"N Shaverdian","year":"2022","unstructured":"Shaverdian N, Shepherd AF, Li X, Offin M, Lengel HB, Gelblum DY, et al. Effects of tumor mutational burden and gene alterations associated with radiation response on outcomes of postoperative radiation therapy in Non-Small cell lung cancer. Int J Radiat Oncol Biol Phys. 2022;113:335\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3659_CR43","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50:645\u201351.","journal-title":"Nat Genet"},{"key":"3659_CR44","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"3659_CR45","doi-asserted-by":"publisher","first-page":"104738","DOI":"10.1016\/j.ebiom.2023.104738","volume":"95","author":"H Fettke","year":"2023","unstructured":"Fettke H, Dai C, Kwan EM, Zheng T, Du P, Ng N, et al. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. EBioMedicine. 2023;95:104738.","journal-title":"EBioMedicine"},{"key":"3659_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/07357907.2021.1899200","volume":"39","author":"Y Fan","year":"2021","unstructured":"Fan Y, Fan H, Quan Z, Wu X. Ionizing radiation combined with PARP1 inhibitor reduces radioresistance in prostate cancer with RB1\/TP53 loss. Cancer Invest. 2021;39:423\u201334.","journal-title":"Cancer Invest"},{"key":"3659_CR47","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1158\/1078-0432.CCR-14-0326","volume":"20","author":"C Thangavel","year":"2014","unstructured":"Thangavel C, Boopathi E, Ciment S, Liu Y, O\u2019Neill R, Sharma A, et al. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. Clin Cancer Res. 2014;20:5468\u201382.","journal-title":"Clin Cancer Res"},{"key":"3659_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/emmm.200900040","volume":"1","author":"SA Martin","year":"2009","unstructured":"Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 2009;1:323\u201337.","journal-title":"EMBO Mol Med"},{"key":"3659_CR49","doi-asserted-by":"crossref","unstructured":"King L, Bernaitis N, Christie D, Chess-Williams R, Sellers D, McDermott C et al. Drivers of radioresistance in prostate cancer. J Clin Med. 2022;11:5637.","DOI":"10.3390\/jcm11195637"},{"key":"3659_CR50","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.","journal-title":"Cell Death Dis"},{"key":"3659_CR51","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41416-021-01438-2","volume":"125","author":"DL Casey","year":"2021","unstructured":"Casey DL, Pitter KL, Wexler LH, Slotkin EK, Gupta GP, Wolden SL. TP53 mutations increase radioresistance in rhabdomyosarcoma and ewing sarcoma. Br J Cancer. 2021;125:576\u201381.","journal-title":"Br J Cancer"},{"key":"3659_CR52","doi-asserted-by":"crossref","unstructured":"Cordani M, Butera G, Pacchiana R, Masetto F, Mullappilly N, Riganti C, Donadelli M, et al. Mutant p53-Associated molecular mechanisms of ROS regulation in cancer cells. Biomolecules. 2020;10:361\u201382.","DOI":"10.3390\/biom10030361"},{"key":"3659_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"3659_CR54","doi-asserted-by":"crossref","unstructured":"Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN. Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer. Urologiia. 2019;5:79\u201385.","DOI":"10.18565\/urology.2019.5.79-85"},{"key":"3659_CR55","unstructured":"Baum RP, Singh V, Zhang A, Sartor J, A; and, Kulkarni H. Germline gene variants and therapy response in patients referred for radioligand therapy with 177Lu-PSMA: A huge step towards pharmacogenomics in theranostics of prostate cancer. J Nuc Med. 2020;61:1272."},{"key":"3659_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-024-00519-1","volume":"13","author":"Z Shi","year":"2024","unstructured":"Shi Z, Hu C, Zheng X, Sun C, Li Q. Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells. Exp Hematol Oncol. 2024;13:55.","journal-title":"Exp Hematol Oncol"},{"key":"3659_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/HP.0000000000001601","volume":"123","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Cao F, Liu H. Radiation-induced cell death and its mechanisms. Health Phys. 2022;123:376\u201386.","journal-title":"Health Phys"},{"key":"3659_CR58","doi-asserted-by":"publisher","first-page":"1583168","DOI":"10.3389\/fonc.2025.1583168","volume":"15","author":"H Beltran","year":"2025","unstructured":"Beltran H, Calais J, Emmett L, Kuo PH, Logothetis CJ. Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Front Oncol. 2025;15:1583168.","journal-title":"Front Oncol"},{"key":"3659_CR59","doi-asserted-by":"crossref","unstructured":"Kao YH, Pook D, Shapiro J, Frydenberg M, Sivaratnam D. Correlation of tumour absorbed dose with progression-free survival in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. Journal of Nuclear Medicine Technology. 2026.","DOI":"10.2967\/jnmt.125.270563"},{"key":"3659_CR60","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic Castration-Resistant prostate cancer: correlations between pretherapeutic imaging and Whole-Body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323.","journal-title":"J Nucl Med"},{"key":"3659_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2024.42.4_suppl.220","volume":"42","author":"M Muniz","year":"2024","unstructured":"Muniz M, Sartor AO, Bobek O, Orme J, Andrews JR, Quevedo F, et al. Genomic predictors of response and resistance to 177-Lu-PSMA-617 using Circulating tumor DNA. J Clin Oncol. 2024;42:220.","journal-title":"J Clin Oncol"},{"key":"3659_CR62","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi U, Sansovini M, Severi S, Nicolini S, Monti M, Gurioli G, et al. Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a phase 2 trial. Br J Cancer. 2021;125:1226\u201332.","journal-title":"Br J Cancer"},{"key":"3659_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-Targeting alpha-Radiation therapy often harbor mutations in DNA Damage-Repair-Associated genes. J Nucl Med. 2020;61:683\u20138.","journal-title":"J Nucl Med"},{"key":"3659_CR64","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","volume":"44","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3659_CR65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, et al. Mechanisms of resistance to prostate-Specific membrane Antigen-Targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 2021;62:989\u201395.","journal-title":"J Nucl Med"},{"key":"3659_CR66","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.7150\/thno.96322","volume":"14","author":"PHJ Slootbeek","year":"2024","unstructured":"Slootbeek PHJ, Luna-Velez MV, Prive BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, et al. Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2024;14:4555\u201369.","journal-title":"Theranostics"},{"key":"3659_CR67","doi-asserted-by":"crossref","unstructured":"Al-Arafat TM, Katsube A, Wang T. B. Exploring the Role of p53 in Radiosensitivity: A Key Player in Cancer Therapy. Radiation 2024;4:309\u2009\u2013\u200924.","DOI":"10.3390\/radiation4040023"},{"key":"3659_CR68","doi-asserted-by":"publisher","first-page":"e1437","DOI":"10.1038\/cddis.2014.415","volume":"5","author":"L Chang","year":"2014","unstructured":"Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. PI3K\/Akt\/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 2014;5:e1437.","journal-title":"Cell Death Dis"},{"key":"3659_CR69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, Tao J, Pathmanandavel S, Boulter N, et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with Lutetium-177-PSMA-617. Eur Urol Open Sci. 2023;57:30\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"3659_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","volume":"53","author":"J Vanwelkenhuyzen","year":"2023","unstructured":"Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, Ustmert S, et al. AR and PI3K genomic profiling of Cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic Castration-resistant prostate cancer. Eur Urol Open Sci. 2023;53:63\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"3659_CR71","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","volume":"31","author":"EM Kwan","year":"2025","unstructured":"Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, et al. Lutetium-177-PSMA-617 or Cabazitaxel in metastatic prostate cancer: Circulating tumor DNA analysis of the randomized phase 2 therap trial. Nat Med. 2025;31:2722\u201336.","journal-title":"Nat Med"},{"key":"3659_CR72","doi-asserted-by":"crossref","unstructured":"Gulati GS, Choueiri TK, Freedman ML, Baca SC. Precision oncology 2.0: Guiding magic bullets with expression-based liquid biopsy. J Clin Oncol. 2026:Jco2501983.","DOI":"10.1200\/JCO-25-01983"},{"key":"3659_CR73","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130:1653\u201368.","journal-title":"J Clin Invest"},{"key":"3659_CR74","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, et al. Noninvasive detection of neuroendocrine prostate cancer through targeted Cell-free DNA methylation. Cancer Discov. 2024;14:424\u201345.","journal-title":"Cancer Discov"},{"key":"3659_CR75","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.21.00169","volume":"39","author":"JM Sperger","year":"2021","unstructured":"Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, et al. Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer. J Clin Oncol. 2021;39:2926\u201337.","journal-title":"J Clin Oncol"},{"key":"3659_CR76","doi-asserted-by":"crossref","unstructured":"Groen L, Kloots I, Englert D, Seto K, Estafanos L, Smith P, et al. Transcriptome profiling of circulating tumor cells to predict clinical outcomes in metastatic castration- resistant prostate cancer. Int J Mol Sci. 2023;24:9002.","DOI":"10.3390\/ijms24109002"},{"key":"3659_CR77","doi-asserted-by":"crossref","unstructured":"Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint Blockade. Sci Transl Med. 2021;13:602.","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"3659_CR78","doi-asserted-by":"crossref","unstructured":"Sagkrioti E, Biz GM, Takan I, Asfa S, Nikitaki Z, Zanni V, et al. Radiation Type- and Dose-Specific transcriptional responses across healthy and diseased mammalian tissues. Antioxidants (Basel). 2022;11:2286.","DOI":"10.3390\/antiox11112286"},{"key":"3659_CR79","doi-asserted-by":"crossref","unstructured":"Handke A, Kesch C, Fendler WP, Telli T, Liu Y, Hakansson A et al. Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy. J Immunother Cancer. 2023;11:e007354.","DOI":"10.1136\/jitc-2023-007354"},{"key":"3659_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cels.2020.12.001","volume":"12","author":"JE Lewis","year":"2021","unstructured":"Lewis JE, Forshaw TE, Boothman DA, Furdui CM, Kemp ML. Personalized Genome-Scale metabolic models identify targets of redox metabolism in Radiation-Resistant tumors. Cell Syst. 2021;12:68\u201381. e11.","journal-title":"Cell Syst"},{"key":"3659_CR81","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/mc.23379","volume":"61","author":"GH Read","year":"2022","unstructured":"Read GH, Bailleul J, Vlashi E, Kesarwala AH. Metabolic response to radiation therapy in cancer. Mol Carcinog. 2022;61:200\u201324.","journal-title":"Mol Carcinog"},{"key":"3659_CR82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:291\u20139.","journal-title":"Lancet Oncol"},{"key":"3659_CR83","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25:1267\u201376.","journal-title":"Lancet Oncol"},{"key":"3659_CR84","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24:1266\u201376.","journal-title":"Lancet Oncol"},{"key":"3659_CR85","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","volume":"66","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, et al. Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials. J Nucl Med. 2025;66:1265\u201370.","journal-title":"J Nucl Med"},{"key":"3659_CR86","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2025.08.3007","volume":"36","author":"SK Sandhu","year":"2025","unstructured":"Sandhu SK, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, et al. 2391P luparp: phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and Olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Ann Oncol. 2025;36:S1300\u20131.","journal-title":"Ann Oncol"},{"key":"3659_CR87","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","volume":"50","author":"L Widjaja","year":"2023","unstructured":"Widjaja L, Werner RA, Krischke E, Christiansen H, Bengel FM, Bogdanova N, Derlin T. Individual radiosensitivity reflected by \u03b3-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50:602\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3659_CR88","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/RLU.0000000000005390","volume":"49","author":"YH Kao","year":"2024","unstructured":"Kao YH, Falzone N, Pearson M, Pook D, Sivaratnam D. 177 Lu-PSMA with Olaparib radiosensitization potentiates response and toxicity in extensive Castration-Resistant metastatic prostate cancer. Clin Nucl Med. 2024;49:966\u20137.","journal-title":"Clin Nucl Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03659-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:12:16Z","timestamp":1781633536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03659-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3659"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03659-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For the establishment of patient-derived xenografts, informed, written consent was obtained from patients prior to tissue collection according to human ethics approval from the Cabrini Institute (RES-20-0000-107\u00a0C; 03-14-04-08), Monash University (1636; 7996) and Peter MacCallum Cancer Centre (11\/102). All animal care and procedures for the establishment, maintenance and treatment of PDXs were performed in accordance with Monash University animal ethics approvals (28911; 31041; 37507; 41088).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R Taylor and G Risbridger have existing research collaborations with Pfizer, Astellas, Zenith Epigenetics, AstraZeneca. M. de Veer has existing contract research projects with Telix Pharmaceuticals that are unrelated to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}